Cohort Studyhigh evidence

Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes.

Nature medicine·March 19, 2026·PMID 41857198

Why it matters

GLP-1RAs are widely used in type 2 diabetes for cardiorenal protection, but long-term outcome data in type 1 diabetes are scarce. This study provides real-world evidence suggesting similar benefits without compromising safety, which could influence off-label use and future guidelines.

Infographic summary of Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled